thor: erdafitinib in metastatic urothelial cancer with fgfr alterations
Published 1 year ago • 137 plays • Length 1:47Download video MP4
Download video MP3
Similar videos
-
1:04
thor: erdafitinib in advanced or metastatic urothelial cancer and fgfr alterations
-
2:31
an update on erdafitinib for metastatic/uresectable fgfr alteration urothelial carcinoma
-
3:37
phase iii thor study: erdafitinib vs. pembrolizumab in fgfr-altered advanced or metastatic uc
-
2:20
erdafitinib /- cetrelimab in muc patients with fgfr alterations
-
1:49
blc2001: erdafitinib for the treatment of metastatic urothelial carcinoma
-
1:49
thor: impact of fgfr3 alterations in muc on subtype and outcomes with erdafitinib vs pembrolizumab
-
1:47
the future role of erdafitinib in advanced urothelial carcinoma
-
3:42
norse: erdafitinib cetrelimab in muc with fgfr alterations
-
1:27
thor-2 cohort 3 interim analysis: erdafitinib in intermediate-risk nmibc with fgfr3/2 alterations
-
4:43
erdafitinib for fgfr-mutated urothelial carcinoma
-
0:49
evolving landscape of urothelial cancer treatment: erdafitinib or enfortumab vedotin?
-
1:27
erdafitinib and enfortumab vedotin in pretreated fgfr2/3-mutant bladder cancer
-
2:12
erdafitinib: one more tool for bladder cancer
-
1:28
erdafitinib for bladder cancer: more to come following fda approval
-
1:59
how can we best sequence novel treatments in urothelial cancer?
-
2:05
the evolving treatment landscape of advanced and metastatic urothelial carcinoma
-
0:43
current developments in fgfr inhibitors for urothelial cancer
-
3:26
blc2001: erdafitinib for muc
-
2:20
the role of erdafitinib in treating patients with bladder cancer